Identification of non-invasive biomarkers for treatment response in neuroblastoma by circulating miRNA profiling

摘要: Introduction: An outstanding question in neuroblastoma treatment is whether clinically useful biomarkers of response to therapy can be identified. Biomarkers that allow monitoring targeted drug pathway activation are highly desirable for the clinical follow-up patients treated with such drugs. Minimally-invasive methods patient follow-up, like measuring expression levels miRNAs serum, may an elegant approach obtain a higher specificity, sensitivity and lower handling time than other currently used biomarkers. Method: MYCN/ALKR1279Q transgenic mice were crizotinib. Mice carrying orthotopic xenografts SH-SY5Y cells RG7388 or temsirolimus. Serum samples these collected at different points before, during after as well matching end-point tumor material. Small RNA sequencing was optimized low input depleted abundant non-relevant sequences. whole miRNome RT-qPCR performed identify circulating responsive cell engraftment. Results: We able observe changes dozens up one hundred miRNAs, some which had >10 fold change value. showed differential both result engraftment. These include known roles biology oncogenic miR-17-92 cluster. Moreover, found possibly drug-specific. Conclusion: data encourage further investigation response, also setting.